AR095496A1 - Formulaciones de anticuerpos anti-receptor de prolactina - Google Patents
Formulaciones de anticuerpos anti-receptor de prolactinaInfo
- Publication number
- AR095496A1 AR095496A1 ARP140101101A ARP140101101A AR095496A1 AR 095496 A1 AR095496 A1 AR 095496A1 AR P140101101 A ARP140101101 A AR P140101101A AR P140101101 A ARP140101101 A AR P140101101A AR 095496 A1 AR095496 A1 AR 095496A1
- Authority
- AR
- Argentina
- Prior art keywords
- prolactin
- formulations
- receiver
- antibodies anti
- prlr antibody
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000003946 Prolactin Human genes 0.000 title 1
- 108010057464 Prolactin Proteins 0.000 title 1
- 229940097325 prolactin Drugs 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 102100029000 Prolactin receptor Human genes 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799629P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095496A1 true AR095496A1 (es) | 2015-10-21 |
Family
ID=50678293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101101A AR095496A1 (es) | 2013-03-15 | 2014-03-14 | Formulaciones de anticuerpos anti-receptor de prolactina |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9023357B2 (OSRAM) |
| EP (1) | EP2968538A1 (OSRAM) |
| JP (1) | JP2016515515A (OSRAM) |
| CN (1) | CN105025925A (OSRAM) |
| AR (1) | AR095496A1 (OSRAM) |
| CA (1) | CA2906101A1 (OSRAM) |
| HK (1) | HK1215175A1 (OSRAM) |
| TW (1) | TW201513882A (OSRAM) |
| UY (1) | UY35460A (OSRAM) |
| WO (1) | WO2014143909A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA036225B1 (ru) | 2012-03-14 | 2020-10-15 | Ридженерон Фармасьютикалз, Инк. | Мультиспецифические антигенсвязывающие молекулы и их применения |
| CN105025925A (zh) * | 2013-03-15 | 2015-11-04 | 拜尔健康护理有限责任公司 | 抗-催乳素受体抗体制剂 |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| JP6993958B2 (ja) | 2015-07-06 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性抗原結合分子およびその使用 |
| JP6897570B2 (ja) | 2015-12-18 | 2021-06-30 | アステラス製薬株式会社 | 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物 |
| IL249795B (en) * | 2016-02-05 | 2020-01-30 | Grifols Worldwide Operations Ltd | Intradermal administration of an immunoglobulin preparation g |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| EP3518971A4 (en) | 2016-09-28 | 2020-05-13 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| MX2019006131A (es) | 2016-11-29 | 2019-08-21 | Regeneron Pharma | Metodos para tratar cancer de mama positivo para prlr. |
| NZ757965A (en) * | 2017-03-16 | 2022-07-01 | Lg Chemical Ltd | Liquid formulation of anti-tnf alpha antibody |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| TWI842672B (zh) | 2017-04-13 | 2024-05-21 | 美商艾吉納斯公司 | 抗ｃｄ１３７抗體及其使用方法 |
| HRP20221448T1 (hr) * | 2018-01-26 | 2023-01-20 | F. Hoffmann - La Roche Ag | Il-22 fc pripravci i postupci njihove primjene |
| AU2019218892B2 (en) | 2018-02-07 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| JP7266108B2 (ja) | 2019-02-18 | 2023-04-27 | イーライ リリー アンド カンパニー | 治療用抗体製剤 |
| WO2024102675A1 (en) | 2022-11-07 | 2024-05-16 | Upstream Bio, Inc. | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2004055164A2 (en) * | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP2423231A3 (en) * | 2006-08-18 | 2012-05-30 | Novartis AG | PRLR-specific antibody and uses thereof |
| US8323653B2 (en) * | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| TW200831133A (en) * | 2006-12-11 | 2008-08-01 | Hoffmann La Roche | Mab Abeta lyophylized formulation |
| EP2109460B1 (en) | 2007-01-11 | 2016-05-18 | Novo Nordisk A/S | Anti-kir antibodies, formulations, and uses thereof |
| RU2010120674A (ru) * | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| JP5524967B2 (ja) * | 2008-09-19 | 2014-06-18 | エフ．ホフマン−ラ ロシュ アーゲー | 新規抗体処方物 |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| WO2010129469A1 (en) * | 2009-05-04 | 2010-11-11 | Abbott Biotechnology Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| EP2332995A1 (en) | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| WO2011080209A2 (en) * | 2009-12-29 | 2011-07-07 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| CN105025925A (zh) * | 2013-03-15 | 2015-11-04 | 拜尔健康护理有限责任公司 | 抗-催乳素受体抗体制剂 |
-
2014
- 2014-03-14 CN CN201480016050.7A patent/CN105025925A/zh active Pending
- 2014-03-14 EP EP14722033.9A patent/EP2968538A1/en not_active Withdrawn
- 2014-03-14 WO PCT/US2014/028078 patent/WO2014143909A1/en not_active Ceased
- 2014-03-14 AR ARP140101101A patent/AR095496A1/es unknown
- 2014-03-14 TW TW103109457A patent/TW201513882A/zh unknown
- 2014-03-14 US US14/213,497 patent/US9023357B2/en active Active
- 2014-03-14 JP JP2016502699A patent/JP2016515515A/ja active Pending
- 2014-03-14 UY UY0001035460A patent/UY35460A/es not_active Application Discontinuation
- 2014-03-14 US US14/772,369 patent/US20160002342A1/en not_active Abandoned
- 2014-03-14 HK HK16103172.6A patent/HK1215175A1/zh unknown
- 2014-03-14 CA CA2906101A patent/CA2906101A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2968538A1 (en) | 2016-01-20 |
| US20160002342A1 (en) | 2016-01-07 |
| TW201513882A (zh) | 2015-04-16 |
| HK1215175A1 (zh) | 2016-08-19 |
| US9023357B2 (en) | 2015-05-05 |
| CN105025925A (zh) | 2015-11-04 |
| JP2016515515A (ja) | 2016-05-30 |
| UY35460A (es) | 2014-10-31 |
| CA2906101A1 (en) | 2014-09-18 |
| US20140271659A1 (en) | 2014-09-18 |
| WO2014143909A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095496A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| AR092401A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr) | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| PE20181400A1 (es) | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab | |
| HRP20191299T1 (hr) | Formulacije protutijela | |
| AR108240A1 (es) | Formulaciones que contienen anticuerpos | |
| ES2676205T3 (es) | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados | |
| PE20190405A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4beta7 | |
| NZ630885A (en) | Antibody formulation | |
| PE20142407A1 (es) | Formulacion de anticuerpos | |
| RU2013148119A (ru) | Лиофилизированный препарат ботулотоксина | |
| MX385109B (es) | Formulaciones de anticuerpos. | |
| SV2018005621A (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| EA201490804A1 (ru) | Препараты этанерцепта, стабилизированные хлоридом натрия | |
| NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| PE20142167A1 (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| AR095396A1 (es) | Formulaciones de anticuerpo | |
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| GT201500046A (es) | Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d | |
| CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| PE20151524A1 (es) | FORMULACIONES DE LA SOLUCION DE LOS ANTICUERPOS ANTI-IL-23p19 MANIPULADOS GENETICAMENTE | |
| WO2018109588A3 (en) | Stable aqueous anti-c5 antibody composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |